Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The SET oncoprotein promotes cancer by inhibiting tumor suppressor PP2A and metastasis suppressor nm23-H1.
• Targeting SET could offer a multi-faceted approach to cancer therapy.

Purpose of the Study:

• Investigate the effects of inhibiting SET oncoprotein function on cancer cell signaling and proliferation.
• Evaluate COG112, a novel SET-interacting peptide, as a potential therapeutic agent.

Main Methods:

• Used human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cell lines.
• Assessed COG112's interaction with SET and its effects on PP2A, nm23-H1, Akt signaling, and Rac1.
• Measured cellular migration and invasion.

Main Results:

• COG112 binds to SET, disrupting SET's inhibitory interaction with PP2A and nm23-H1.
• COG112 treatment increases PP2A and nm23-H1 activities, inhibiting Akt signaling, proliferation, migration, and invasion.
• COG112 also inhibits SET association with Rac1, further reducing cancer cell motility.

Conclusions:

• SET is a viable molecular target for cancer therapy.
• Inhibiting SET with agents like COG112 can restore tumor and metastasis suppressor functions, showing promise for cancer chemotherapy.